(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Bombardier Global 8000 Enters Service - 2Danish warship sunk by famed British admiral discovered after 225 years
- 3The Reduced Portage Horse: An Inheritance Reconsidered for Present day Experience
- 4Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- 5Tablets: Upgrade Your Understanding Experience
- Figure out How to Involve a Brain science Certification in Showcasing
- The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- Select Your Go-To Bluetooth Earphones
- Why More Couples Are Choosing Africa For Their Honeymoon
- Mussolini's summer villa on Adriatic coast sold for €1.2 million
- Authorities Bust Camel Booze Smuggling Operation, Seize Nearly 2,000 Containers of Illegal Alcohol
- After toilet and email issues, Artemis II astronauts fire engine to head for the moon
- 10 High priority Contraptions for Tech Aficionados
- 'Fertiliser costs mean I'm better off not planting'
